孕激素治疗子宫内膜异位症的研究进展被引量：4

Research progress of progestins in endometriosis treatment

导出

摘要孕激素受体是配体激活的核转录调节因子,其配体包含天然孕激素、孕激素衍生物及合成孕激素等。子宫内膜异位症是雌激素依赖的炎症性疾病,孕激素类药物作用于异位病灶可以起到拮抗雌激素、抗炎、抗血管神经生成及促凋亡的作用。然而,子宫内膜异位症存在孕激素抵抗等病因学因素,孕激素类药物并不能对所有子宫内膜异位症患者起到令人满意的治疗效果。本文将对孕激素受体配体治疗子宫内膜异位症的机制、影响疗效的因素及改善疗效的策略进行综述,为子宫内膜异位症的药物治疗提供新的思路。 Progesterone receptor is ligands-activated nuclear transcription regulator,the ligands including natural progesterone,progesterone derivatives and synthetic progesterone.Endometriosis is estrogen-dependent inflammatory disease,progestins can induce anti-estrogenic,anti-inflammatory,anti-neuroangiogenesis and pro-apoptotic effects to endometriotic lesions.However,owing progesterone resistance and other etiological factors of endometriosis,progestins sometimes cannot achieve satisfactory therapeutic effects.This review focused on the mechanism of progesterone receptor ligands influencing endometriosis medical therapeutic effects,which may help to give novel clues to endometriosis drug therapy.

作者黄新黄薇 Huang Xin;Huang Wei(Division of Reproductive Medicine,West China Second University Hospital of Sichuan University,Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education,Chengdu 610041,China)

机构地区四川大学华西第二医院生殖医学科出生缺陷与相关妇儿疾病教育部重点实验室

出处《中华生殖与避孕杂志》 CAS CSCD 北大核心 2022年第9期962-966,共5页 Chinese Journal of Reproduction and Contraception

基金国家重大研发计划(2017YFC1001202-2) 国家自然科学基金面上项目(82071625) 四川省科学技术厅重点研发项目(2021YFS0028)。

关键词孕激素受体子宫内膜异位症药物治疗孕激素抵抗 Progesterone receptor Endometriosis Drug therapy Progesterone resistance

分类号 R711.71 [医药卫生—妇产科学]

引文网络
相关文献

参考文献1

1辛启亮,邱静涛,崔胜,夏国良,王海滨.雌、孕激素受体的转录激活与调控（英文）[J].生理学报,2016,68(4):435-454. 被引量：6

二级参考文献191

1McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002; 108(4): 465-474.
2Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451-486.
3Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999; 20(3): 358-417.
4Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 2006; 58(4): 782-797.
5Bain DL, Connaghan KD, Maluf NK, Yang Q, Miura MT, De Angelis RW, Degala GD, Lambert JR. Steroid receptorDNA interactions: toward a quantitative connection between energetics and transcriptional regulation. Nucleic Acids Res 2014; 42(2): 691-700.
6Nagy L, Schwabe JW. Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 2004; 29(6): 317- 324.
7Cato L, Neeb A, Brown M, Cato AC. Control of steroid receptor dynamics and function by genomic actions of the cochaperones p23and Bag-lL. Nucl Recept Signal 2014; 12: e005.
8Ismail A, Nawaz Z. Nuclear hormone receptor degradation and gene transcription: an update. IUBMB Life 2005; 57(7): 483-490.
9Shemshedini L, Ji JW, Brou C, Chambon P, Gronemeyer H. In vitro activity of the transcription activation functions of the progesterone receptor. Evidence for intermediary factors. J Bioi Chern 1992; 267(3): 1834-1839.
10Faus H, Haendler B. Post-translational modifications of steroid receptors. Biomed Pharmacother 2006; 60(9): 520- 528.